These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23441974)

  • 1. Real-world treatment pattern and outcomes among patients who took tapentadol IR or oxycodone IR.
    Lin J; Chow W; Kim MS; Rupnow MF
    J Med Econ; 2013; 16(5):685-90. PubMed ID: 23441974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.
    Neil N; Merchant S; Provenzano D; Ogden K; Mody SH
    J Med Econ; 2013; 16(2):307-17. PubMed ID: 23216013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
    Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
    Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
    Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
    J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl.
    Kirson NY; White AG; Birnbaum HG; Schiller M; Waldman T; Peterson K; Ben-Joseph RH; Berner T; Summers KH
    J Med Econ; 2012; 15(1):87-95. PubMed ID: 22032675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain.
    Kwong WJ; Ozer-Stillman I; Miller JD; Haber NA; Russell MW; Kavanagh S
    Clin Ther; 2010 Sep; 32(10):1768-81. PubMed ID: 21194601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain.
    Daniels S; Casson E; Stegmann JU; Oh C; Okamoto A; Rauschkolb C; Upmalis D
    Curr Med Res Opin; 2009 Jun; 25(6):1551-61. PubMed ID: 19445652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study.
    Cepeda MS; Fife D; Ma Q; Ryan PB
    J Pain; 2013 Oct; 14(10):1227-41. PubMed ID: 23850177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain.
    Kwong WJ; Diels J; Kavanagh S
    Ann Pharmacother; 2010 Apr; 44(4):630-40. PubMed ID: 20197473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain.
    Kwong WJ; Hammond G; Upmalis D; Okamoto A; Yang M; Kavanagh S
    Clin J Pain; 2013 Aug; 29(8):664-72. PubMed ID: 23835764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and economical evaluation of new analgesics for the management of chronic pain].
    Coluzzi F; Ruggeri M
    Recenti Prog Med; 2014 Nov; 105(11):415-9. PubMed ID: 25424235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
    Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
    J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Baker RA; Karson C
    J Med Econ; 2013; 16(4):522-8. PubMed ID: 23360177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
    Etropolski M; Kelly K; Okamoto A; Rauschkolb C
    Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
    Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
    Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
    Eby EL; Boye KS; Lage MJ
    J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
    Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans.
    Ben-Joseph R; Chen CC; De AP; Wade RL; Shah D
    J Med Econ; 2014 Oct; 17(10):708-18. PubMed ID: 24888403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.